Arnon Nagler

127PUBLICATIONS
341CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Transplantation immunologyHaematologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (127)

|Sep 30, 2026
Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

|Sep 10, 2026
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.

|Sep 03, 2026
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.

|Aug 11, 2026
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee.

|Jul 20, 2026
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

|Jul 17, 2026
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Pageof 22

Frequent Collaborators

65 joint publications

Mohamad Mohty

52 joint publications

Myriam Labopin

46 joint publications

Fabio Ciceri

34 joint publications

Didier Blaise